慢性心力衰竭患者的血清可溶性Fas配体和可溶性Fas受体

目的 分析血清可溶性Fas配体(sFasL)和可溶性Fas受体(sEas)与慢性心力衰竭(CHF)的相关性。方法采用酶联免疫吸附双抗体夹心法检测33例CHF患者(CHF组,心功能Ⅱ-Ⅳ级,NYHA)血清sFasL和sFas浓度,并与18例心功能Ⅰ级(NYHA)组比较。结果 CHF与心功能Ⅰ级间sFasL浓度无显著统计学差异231.50±84.50(心功能Ⅱ级216.50±96.00,Ⅲ级226.80±85.70,Ⅳ级244.00±73.00)vs217.50±89.00pg/mL,P>0.05]。而CHF组血清sFas浓度显著高于心功能Ⅰ级组1353.30±507.71(心功能Ⅱ级1154.85±371.20,Ⅲ级1412.88±493.62,Ⅳ级1875.67±806.10)vs983.11±461.26pg/mL,P<0.05]。结论 血清sFasL与CHF无相关性。而血清sFas与CHF存在显著相关性。且sFas浓度增高的程度与CHF的严重程度相平行,sFas浓度增高可能在CHF发病机制中起重要作用。

The serum levels of soluble Fas ligand and soluble Fas receptor in patinets with chronic congestive heart failure

Objectives To investigate the association of soluble Fas ligand (sFasL) and soluble Fas receptor (sFas) with human chronic congestive heart failure (CHF). Methods The serum level of sFsL and sFas in 33 patients with CHF (13 in cardiac function class II , 17 in clsss III , 3 in class IV, NYHA) was assessed with enzyme-linked immunosorbent assay, and was compared with that of 18 age-, blood pressure-matched patients with cardiac function class I (NYHA). Results There was no difference in the level of sFasL between the two groups CHF group: 231.50 +84.50 (cardiac function class II 216. 50 + 96.00, class 1 226.80+ 85.70, class IV 244.00+ 73.00) vs cardiac function class I group: 217.50 + 89.00 pg/mL, P , 0.05]. However, the level of sFas was significantly ingher in the patients with CHF than those of cardiac function class I group CHF group: 1 353.30 + 507.71 (cardiac function class II 1 154.85 + 371.20, class 1 1 412. 88 + 493. 62, class IV 1 875.67 + 806.10) vs cardiac function class I group: 983. 11 + 461. 26 pg/mL, P < 0.05]. Conclusions sFasL was not associated with human CHF. However, the elevation of serum level of sFas was proportion to the severity of human CHF. sFas may play an important role in the pathogenesis of human CHF.